Lung function trajectories in patients with idiopathic pulmonary fibrosis

被引:7
|
作者
Neely, Megan L. [1 ,2 ]
Hellkamp, Anne S. [1 ,2 ]
Bender, Shaun [3 ]
Todd, Jamie L. [1 ,2 ]
Liesching, Timothy [4 ]
Luckhardt, Tracy R. [5 ]
Oldham, Justin M. [6 ]
Raj, Rishi [7 ]
White, Eric S. [3 ]
Palmer, Scott M. [1 ,2 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27701 USA
[2] Duke Univ, Med Ctr, Durham, NC 27710 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[4] Lahey Hosp & Med Ctr, Burlington, MA USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
[6] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[7] Stanford Univ, Sch Med, Stanford, CA USA
关键词
Interstitial lung disease; Lung function testing; Forced vital capacity; FORCED VITAL CAPACITY; CLINICAL-COURSE; INTERSTITIAL PNEUMONIA; SURVIVAL; PROGRESSION; MORTALITY; PIRFENIDONE; SPIROMETRY; NINTEDANIB; EFFICACY;
D O I
10.1186/s12931-023-02503-5
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.Methods Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns. Results Of 1002 patients in the registry, 941 had = 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.Conclusions Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Lung Transplant Listing of Idiopathic Pulmonary Fibrosis Patients at Pulmonary Fibrosis Care Centers
    Mooney, J.
    Moore, J.
    Raj, R.
    Dhillon, G.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S335 - S335
  • [42] Pulmonary Blood Mass and Quantitative Lung Function Imaging in Idiopathic Pulmonary Fibrosis
    Nair, Girish B.
    Al-Katib, Sayf
    Castillo, Edward
    RADIOLOGY-CARDIOTHORACIC IMAGING, 2020, 2 (03):
  • [43] A Comparison of Pulmonary Function Test (PFT) Trajectories in Idiopathic Pulmonary Fibrosis (IPF) and Combined Pulmonary Fibrosis and Emphysema (CPFE) Syndrome
    Huntley, Christopher C.
    Ellis, Paul
    Kanabar, Shivani
    Armitage, Michael N.
    Mitra, Pathrabali
    Thomas, Maximillian
    Burge, P. Sherwood
    Walters, Gareth, I
    Turner, Alice M.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [44] Lung transplantation in patients with interstitial lung disease/idiopathic pulmonary fibrosis
    Murer, Christian
    Benden, Christian
    THERAPEUTISCHE UMSCHAU, 2016, 73 (01) : 43 - 45
  • [45] Impaired lung NK activity in the lung of Idiopathic Pulmonary Fibrosis patients
    Cruz, Tamara
    Bondonese, Anna
    Sembrat, John
    Tabib, Tracy
    Zhang, Wenping
    Mitash, Nilay
    Vignali, Dario
    Mora, Ana L.
    Lafyatis, Robert
    Rojas, Mauricio
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [46] The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPP)/ combined pulmonary fibrosis and emphysema (CPFE)
    Cottin, Vincent
    Hansen, David
    Antoniou, Katerina
    Nair, Arjun
    Atwood, Mark
    Sverzellati, Nicola
    Oster, Gerry
    Weycker, Derek
    Collard, Harold R.
    Wells, Athol
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [47] Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis
    Nyilas, Sylvia
    Schreder, Theresa
    Singer, Florian
    Poellinger, Alexander
    Geiser, Thomas Kurt
    Latzin, Philipp
    Funke, Manuela
    RESPIROLOGY, 2018, 23 (08) : 764 - 770
  • [48] Effects of low dose pirfenidone on lung function for patients with idiopathic pulmonary fibrosis in real practice
    Moon, K. M.
    Jung, B.
    Lee, J. G.
    Kim, M. P.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [49] Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
    Jürgen Behr
    Maurits Demedts
    Roland Buhl
    Ulrich Costabel
    Richard PN Dekhuijzen
    Henk M Jansen
    William MacNee
    Michiel Thomeer
    Benoit Wallaert
    Francois Laurent
    Andrew G Nicholson
    Eric K Verbeken
    Johny Verschakelen
    CDR Flower
    Stefano Petruzzelli
    Paul De Vuyst
    van den JMM Bosch
    Eulogio Rodriguez-Becerra
    Ida Lankhorst
    Marco Sardina
    Gabrielle Boissard
    Respiratory Research, 10
  • [50] Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification
    Egan, JJ
    Martinez, FJ
    Wells, AU
    Williams, T
    THORAX, 2005, 60 (04) : 270 - 273